Key facts
- It has raised $4.5M; the latest was Early Stage VC ($4.5M) in Feb 2025.
- Notable investors include Better Angle, GO Capital, Evolem, Angels Santé, Business Angels — 9 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Sirius NeoSight
- ·The full record, as it builds
Funding rounds
No funding rounds for Sirius NeoSight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sirius NeoSight
Developer of a healthcare technology designed to detect and isolate circulating tumour cells for early cancer diagnosis and therapy guidance. The company offers a patented method measuring membrane fluidity, enabling physicians and researchers, the ability to monitor treatment response and adjust therapies for aggressive and metastatic cancers.
- Sector
- Healthcare
- HQ
- Tassin-la-Demi-Lune, France
- Founded
- 2023
- Employees
- 8
- Website
- sirius-neosight.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Sirius NeoSight doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sirius NeoSight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sirius NeoSight in its N-PORT filings yet. We sweep new filings monthly.